Stock CORT CORCEPT THERAPEUTICS INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Corcept Therapeutics Incorporated

Equities

CORT

US2183521028

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
22.8 USD +2.66% Intraday chart for Corcept Therapeutics Incorporated -0.65% -29.80%
Apr. 22 Corcept Therapeutics Incorporated Announces Positive Results from Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients with Cushing?s Syndrome CI
Apr. 15 Corcept Completes Enrollment in Phase 2 Dazals Trial in Patients with Amyotrophic Lateral Sclerosis CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,383 3,039 2,097 2,186 3,348 2,367 - -
Enterprise Value (EV) 1 1,383 3,039 2,097 2,186 2,980 1,847 1,747 2,367
P/E ratio 15.7 x 30.8 x 22.2 x 23.3 x 34.6 x 22.4 x 14.5 x 11.9 x
Yield - - - - - - - -
Capitalization / Revenue 4.51 x 8.59 x 5.73 x 5.44 x 6.94 x 3.88 x 3.36 x 3.02 x
EV / Revenue 4.51 x 8.59 x 5.73 x 5.44 x 6.18 x 3.02 x 2.48 x 3.02 x
EV / EBITDA 12.3 x 23.6 x 16.7 x 14 x - 13.5 x 8.07 x 8.19 x
EV / FCF 10.2 x 20.2 x 12.5 x - 23.5 x 10.5 x 8.73 x -
FCF Yield 9.76% 4.96% 7.98% - 4.26% 9.48% 11.5% -
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 114,281 116,173 105,934 107,650 103,081 103,837 - -
Reference price 2 12.10 26.16 19.80 20.31 32.48 22.80 22.80 22.80
Announcement Date 2/20/20 2/8/21 2/15/22 2/28/23 2/15/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 306.5 353.9 366 401.9 482.4 610.6 704.6 784
EBITDA 1 112.3 128.7 125.5 155.9 - 136.8 216.5 289.2
EBIT 1 111.6 128.2 124.5 112.6 107.3 131.6 214.3 279.6
Operating Margin 36.41% 36.23% 34.01% 28.03% 22.24% 21.56% 30.42% 35.66%
Earnings before Tax (EBT) 1 116.7 131.6 125 116.2 124.6 141.7 225 290.4
Net income 1 94.18 106 112.5 101.3 105.5 116.7 182.6 234.9
Net margin 30.73% 29.96% 30.74% 25.2% 21.87% 19.12% 25.92% 29.97%
EPS 2 0.7700 0.8500 0.8900 0.8700 0.9400 1.020 1.570 1.923
Free Cash Flow 1 135 150.7 167.4 - 126.9 175.1 200.1 -
FCF margin 44.06% 42.58% 45.75% - 26.31% 28.68% 28.41% -
FCF Conversion (EBITDA) 120.23% 117.07% 133.35% - - 128.02% 92.44% -
FCF Conversion (Net income) 143.37% 142.16% 148.8% - 120.29% 150.01% 109.58% -
Dividend per Share - - - - - - - -
Announcement Date 2/20/20 2/8/21 2/15/22 2/28/23 2/15/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 96.13 98.82 93.69 103.4 101.7 103.1 105.7 117.7 123.6 135.4 141.2 150.7 156 162.7 153.6
EBITDA - 36.95 37.82 42.15 42.68 33.2 26.17 29.77 - - - - - - -
EBIT 1 36.23 36.66 26.77 31.43 31.93 22.5 14.85 29.58 31.18 31.67 27.82 32.41 34.41 38.19 30.74
Operating Margin 37.69% 37.1% 28.57% 30.4% 31.39% 21.83% 14.06% 25.13% 25.22% 23.39% 19.7% 21.51% 22.06% 23.47% 20.02%
Earnings before Tax (EBT) 1 36.3 36.74 26.85 32.06 33 24.28 18.43 32.93 36.38 36.81 30.61 35.06 36.96 40.32 35.46
Net income 1 30.47 32.05 22.8 27.4 34.55 16.55 15.81 27.36 31.17 31.14 25.25 28.92 30.51 33.33 28.97
Net margin 31.7% 32.44% 24.33% 26.5% 33.96% 16.06% 14.96% 23.24% 25.22% 23% 17.88% 19.19% 19.56% 20.48% 18.86%
EPS 2 0.2400 0.2600 0.2000 0.2400 0.3000 0.1400 0.1400 0.2500 0.2800 0.2800 0.2200 0.2540 0.2680 0.2920 0.2650
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/3/21 2/15/22 5/5/22 8/3/22 11/3/22 2/28/23 5/3/23 8/2/23 11/1/23 2/15/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - - - - 368 521 621 -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 135 151 167 - 127 175 200 -
ROE (net income / shareholders' equity) 29.1% 23.7% 25% - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - 1.330 - - - - -
Capex 1 1.09 1.24 0.47 0.41 0.14 0.36 0.42 0.5
Capex / Sales 0.35% 0.35% 0.13% 0.1% 0.03% 0.06% 0.06% 0.06%
Announcement Date 2/20/20 2/8/21 2/15/22 2/28/23 2/15/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Corcept Therapeutics Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
22.8 USD
Average target price
42.8 USD
Spread / Average Target
+87.72%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
CORCEPT THERAPEUTICS INCORPORATED Stock Corcept Therapeutics Incorporated
-29.80% 2.37B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CORT Stock
  4. Financials Corcept Therapeutics Incorporated